MINNEAPOLIS–(BUSINESS WIRE)–Humanetics Corporation, an advanced clinical-stage specialty pharmaceutical company pioneering novel medical countermeasures for military use and applicable civilian clinical indications, today announced that the U.S. Food and Drug Administration (FDA) has notified the Company that the clinical investigation under its Investigational New Drug (IND) application for BIO 300 Injectable Suspension (IS) may proceed; accordingly, the IND has been opened. BIO 300 Injectab

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.